Generation Bio, a Cambridge, MA-based gene therapy company, closed a $110m Series C financing.

The company intends to use the funds to advance its two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU) into IND-enabling studies and clinical development.

Led by Geoff McDonough, M.D., president and chief executive officer, Generation Bio is a biotechnology company leading a new generation of re-dosable long-lasting gene therapy.

Its non-viral platform combines three technologies: a novel cell-targeted lipid nanoparticle delivery system (ctLNP), a proprietary closed-ended DNA construct (ceDNA) and a high-capacity capsid-free biologics manufacturing process.

In addition to its lead liver-targeted programs in hemophilia A and phenylketonuria (PKU), Generation Bio is developing gene therapies for patients with diseases of skeletal muscle and the eye. | To read full story, visit https://startuparound.com/read/1578663007.6490245/Generation-Bio-Raises-$110M-in-Series-C-Financing?ref=audio_experience